Naaju Breaking News, Live Updates, Latest Headlines, Viral News, Top Stories, Trending Topics, Videos
[ad_1]
Convalescent plasma has become one of the most widely used treatments for coronavirus, but a new study published in the British journal The Lancet indicated that no significant benefit was seen when using it against covid.
Plasma is a transparent and yellowish liquid which represents more than half of the total volume of blood and is obtained by a procedure which consists in separating the cells with a machine and thus obtaining the different components of the blood: red blood cells, platelets and plasma. The latter is separated into a volume to be defined for each donor.
The Food and Drug Administration of the United Statess (FDA) issued Emergency Use Authorization (EUA) for experimental convalescent plasma as a treatment coronavirus. But despite its massive use, several studies have shown that convalescent plasma does not provide a clear benefit for patient recovery.
In a study conducted in 177 hospitals in UK “High titer convalescent plasma has been shown to not improve survival or other predefined clinical outcomes,” said the experts.
Between May 28, 2020 and January 15, 2021, 11,558 (71%) of the 16,287 patients included in the study were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group.
The study did not find significant differences in 28-day mortality between the two groups assessed.1,399 (24%) of 5,795 patients in the convalescent plasma group and 1,408 (24%) of 5,763 patients in the usual care group died within 28 days.
The 28-day mortality rate was similar in all predefined patient subgroups, even in patients without detectable antibodies to SARS-CoV-2 at randomization, ”they said.
Assignment to convalescent plasma had no significant effect on the proportion of patients discharged within 28 days.
“Among those who did not receive invasive mechanical ventilation at the time of randomization, there was no significant difference in the proportion of patients who achieved the combined endpoint of progression to invasive mechanical ventilation or death (1568 of the 5,493 patients in the group). against 1,568 out of 5,448 patients in the usual care group), the experts said.
“Although observational studies have suggested that convalescent plasma may reduce mortality in severe viral respiratory infections, evidence from randomized trials remains scarce and inconclusive,” the study said.
And they concluded: The effectiveness of convalescent plasma as a treatment for patients hospitalized with covid-19 is uncertain.
The study was conducted by RECOVERY which is an adaptive, open-label, individually controlled and randomized platform trial to evaluate the effects of different potential treatments in hospitalized patients with coronavirus.
.
[ad_2]
Source link
